… ProQR Announces Closing of Underwritten Public Offering and … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through … and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR. …
… ProQR Announces Conference Call to Discuss the Axiomer® RNA … & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY.
… ProQR to Present at the H.C. Wainwright Global Life Sciences … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Appoints David M. Rodman, MD as Chief Development … the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it … of RNA approaches to treating disease.” said Noreen R. Henig, MD, Chief Medical Officer. “There are very few …
… ProQR Announces Clinical Data Presentations and Investor & … the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … 27 Noreen Henig, M.D., Chief Development Officer of ProQR and John P. Clancy, M.D., principal investigator, …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, chief executive officer of ProQR. “Both sepofarsen for LCA10, the most common cause of …
… ProQR Announces Presentations on Programs in Ophthalmology at … LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … II Presentation at OIS Retina Daniel de Boer, CEO of ProQR, will give a presentation highlighting the company’s …